Tetralogy of Fallot News and Research

RSS

Young age and small body weight predispose pediatric CHD patients toward re-intervention

A retrospective review of 633 adults and children who underwent bioprosthetic pulmonary valve replacement (PVR) for congenital heart disease between 1996 and 2014 indicated that the risk of re-intervention was five times greater for children than adults, with the likelihood of re-intervention decreasing by 10% for each increasing year of age at surgery.

29 Apr 2015

New pediatric heart-defect patches enhance electrical connections between cells

Carbon nanotubes serve as bridges that allow electrical signals to pass unhindered through new pediatric heart-defect patches invented at Rice University and Texas Children's Hospital.

24 Sep 2014

Vera and Paul Guerin Family Congenital Heart Program to be established in Cedars-Sinai Heart Institute

In an effort to lengthen the life span and improve the quality of life for those born with heart defects, longtime Cedars-Sinai supporters Vera and Paul Guerin have donated $10 million to establish the Vera and Paul Guerin Family Congenital Heart Program in the Cedars-Sinai Heart Institute.

20 Sep 2013

New biocompatible patch can repair congenital heart defects

A painstaking effort to create a biocompatible patch to heal infant hearts is paying off at Rice University and Texas Children's Hospital.

13 Dec 2012

UAB first hospital in Alabama to offer Melody Valve replacement

In many ways Dylan Fields is your typical 15-year-old boy. He loves sports, and plays baseball and soccer for his school, Tallassee High, in Central Alabama. What's not typical about Dylan is his heart defect and, now, the procedure used to repair his heart.

6 Mar 2012

News briefs from featured presentations at Cardiology 2012

Pediatric cardiology researchers and clinicians from almost 50 centers from across the U.S. and around the world are gathering at the Cardiology 2012 Conference sponsored by The Children's Hospital of Philadelphia on Feb. 22-26 in Orlando, Fla.

27 Feb 2012

Role of cardiovascular magnetic resonance in clinical cardiology

Cardiovascular Magnetic Resonance (CMR) has undergone substantial development and offers important advantages compared with other well-established imaging modalities.

3 Nov 2011

CHOP, Albert Einstein College of Medicine to study genetics of conotruncal defects

The Eunice Kennedy Shriver National Institute of Child Health & Human Development, part of the National Institutes of Health, has awarded researchers at Albert Einstein College of Medicine of Yeshiva University and collaborators at the Children's Hospital of Philadelphia (CHOP) a five-year, $6.7 million grant to study the genetics of both rare and common congenital heart abnormalities known as conotruncal defects.

12 Oct 2011

Non-Hispanic black infants born with heart defects more likely to die within five years

Non-Hispanic black infants born with heart defects are more likely to die within the first five years of life than their non-Hispanic white and Hispanic peers. For certain types of congenital heart abnormalities, Hispanic children as well as non-Hispanic black children fare worse than non-Hispanic white children.

18 Apr 2011

CryoPatch SG pulmonary human cardiac patch receives FDA clearance for 5-year shelf-life extension

CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, today announced that it has received 510(k) clearance from the Food and Drug Administration (FDA) for a five-year shelf-life on its CryoPatch® SG pulmonary human cardiac patch processed with the Company's proprietary SynerGraft® technology. CryoLife's SynerGraft technology is designed to remove allogeneic donor cells and cellular remnants from tissue without compromising the integrity of the underlying collagen matrix.

9 Aug 2010

New Melody Transcatheter Pulmonary valve helps congenital heart defect patients avoid multiple surgeries

Congenital heart defects are the most common type of major birth defect in the U.S., affecting about 25,000 babies each year. Now, a new valve being used at the University of Michigan's C.S. Mott Children's Hospital Congenital Heart Center can help patients delay or avoid multiple surgeries.

13 May 2010

Manuscript on KBR method to be published in American Journal of Cardiology

VentriPoint Diagnostics Ltd. ("VentriPoint" or the "Corporation") is pleased to announce that the manuscript entitled, "Accuracy of Knowledge Based Reconstruction (KBR) for Measurement of Right Ventricular Volume and Function in Patients with Tetralogy of Fallot" has been accepted for publication in the American Journal of Cardiology.

9 Dec 2009

Human-derived UCB stem cell transplant has positive therapeutic effects on specific lung and heart disorders

Two separate studies published in the current issue of Cell Transplantation (18:8), - now freely available on-line at http://www.ingentaconnect.com/content/cog/ct - have shown that transplanted human-derived umbilical cord blood (UCB) stem cells transplanted in an animal model had positive therapeutic effects on specific lung and heart disorders the animal models.

24 Nov 2009

Transcatheter valve may eliminate repeat surgeries in children with heart defects; multicenter study shows good outcomes

Children born with certain heart defects have impaired blood flow from the right ventricle to the pulmonary artery leading to the lungs, requiring implanted devices (known as right-ventricular outflow tract conduits) to maintain the flow. However, these conduits fail over time, and children typically face multiple open-heart operations during their lives to reopen the passage.

27 Oct 2009

CryoValve SG aortic human heart valve receives Humanitarian Use Device designation

CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, today announced that it has received a Humanitarian Use Device (HUD) designation from the Food and Drug Administration (FDA) for its CryoValve® SG aortic human heart valve.

6 Oct 2009

CryoLife's SynerGraft technology effective in removing donor cells and cellular remnants from the tissue

CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, today announced the first three implantations of the CryoPatch((R)) SG pulmonary human cardiac patch since FDA clearance.

19 Aug 2009

Cryolife receives 510(k) clearance from FDA for CryoPatch SG pulmonary human cardiac patch

CryoLife, Inc., (NYSE: CRY) an implantable biological medical device and cardiovascular tissue processing company, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its CryoPatch((R)) SG pulmonary human cardiac patch.

12 Aug 2009

Iraqi child undergoes heart surgery in New York

Four-year old Bra’a Hussein’s heart will never be the same following recent surgery at NYU Medical Center to correct a highly complex congenital heart condition called tetralogy of fallot.

19 Jul 2004